Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205012 | 0.81 | CYP2C9 (0.32) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL3676714 | 0.69 | — | — | |
| SCHEMBL608314 | 0.64 | — | — | |
| SCHEMBL14541307 | 0.64 | — | — | |
| SCHEMBL14818802 | 0.63 | ADORA2A (0.33) | — | |
| SCHEMBL609724 | 0.63 | CYP2C9 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13563915 | 0.61 | CYP2C9 (0.58) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL360382 | 0.60 | — | — | |
| SCHEMBL22541344 | 0.59 | TSHR (0.55) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Iodide SCHEMBL7057387 | 0.59 | CYP2C9 (0.50) | CYP2C9TSHRCYP2C19MTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | CYP2C9 3198/4885TSHR 3733/4885CYP2C19 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.